Glp 1 Drug
-
{
- All
- News
-
Wegovy Pill Users Lost Up To 21.6% Weight In New Obesity Trial
The findings come from Novo Nordisk's phase 3 OASIS 4 clinical trial studying oral semaglutide 25 mg, the same active ingredient used in injectable Wegovy.
-
GLP-1 Drugs May Trigger Muscle Loss In Cirrhosis Patients: Study
GLP-1 drugs are often praised for their metabolic benefits, including improved blood sugar control and weight reduction. However, in patients with liver cirrhosis, these benefits may come with trade-offs.
-
Beyond GLP-1: New 5-In-1 Compound More Effective Than Semaglutide For Diabetes And Weight Loss
This innovative compound is known as a 'quintuple agonist' because it combines the power of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists with lanifibranor.
-
Is Erectile Dysfunction A Side Effect Of Taking Weight-Loss Drugs? New Trial Results Say Yes
A new study links GLP-1 drugs, used for diabetes and weight loss, to a higher risk of erectile dysfunction.
-
New Study Explains Why Ozempic Doesn't Work For Everyone
A new study published in Genome Medicine details that Ozempic doesn't work for everyone in the same manner. Here is what you need to know about its mechanisms and why making science-based medical decisions is important.
-
GLP-1 Should Not Be Used As A Quick Fix For Weight Loss And Diabetes Management, Warns Top Experts
Experts warn that GLP1 drugs like Ozempic and Wegovy aren't quick fixes. There are misuse risks that are involved as shortages, side effects, and weight regain are possible without medical supervision.
-
"Ozempic Personality" And The Dopamine Shift: The Mental Health Side Effects Of Using Ozempic For Weight Loss
Ozempic personality is a psychological impact of using Ozempic for weight loss. You need to know the possible side effects on your mental health to be careful.
-
New Study Finds Diabetes, Weight Loss Drugs May Lower Rheumatoid Arthritis Flares
A study presented at ACR Convergence 2025 suggests that GLP 1 receptor agonists reduce flares and systemic inflammation in Rheumatoid Arthritis (RA) patients.
-
Wegovy Pill Users Lost Up To 21.6% Weight In New Obesity Trial
The findings come from Novo Nordisk's phase 3 OASIS 4 clinical trial studying oral semaglutide 25 mg, the same active ingredient used in injectable Wegovy.
-
GLP-1 Drugs May Trigger Muscle Loss In Cirrhosis Patients: Study
GLP-1 drugs are often praised for their metabolic benefits, including improved blood sugar control and weight reduction. However, in patients with liver cirrhosis, these benefits may come with trade-offs.
-
Beyond GLP-1: New 5-In-1 Compound More Effective Than Semaglutide For Diabetes And Weight Loss
This innovative compound is known as a 'quintuple agonist' because it combines the power of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists with lanifibranor.
-
Is Erectile Dysfunction A Side Effect Of Taking Weight-Loss Drugs? New Trial Results Say Yes
A new study links GLP-1 drugs, used for diabetes and weight loss, to a higher risk of erectile dysfunction.
-
New Study Explains Why Ozempic Doesn't Work For Everyone
A new study published in Genome Medicine details that Ozempic doesn't work for everyone in the same manner. Here is what you need to know about its mechanisms and why making science-based medical decisions is important.
-
GLP-1 Should Not Be Used As A Quick Fix For Weight Loss And Diabetes Management, Warns Top Experts
Experts warn that GLP1 drugs like Ozempic and Wegovy aren't quick fixes. There are misuse risks that are involved as shortages, side effects, and weight regain are possible without medical supervision.
-
"Ozempic Personality" And The Dopamine Shift: The Mental Health Side Effects Of Using Ozempic For Weight Loss
Ozempic personality is a psychological impact of using Ozempic for weight loss. You need to know the possible side effects on your mental health to be careful.
-
New Study Finds Diabetes, Weight Loss Drugs May Lower Rheumatoid Arthritis Flares
A study presented at ACR Convergence 2025 suggests that GLP 1 receptor agonists reduce flares and systemic inflammation in Rheumatoid Arthritis (RA) patients.
